Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias

NCT07224139 · View on ClinicalTrials.gov ↗

Study Summary

Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for personalized medicine and clinical trials.

Study Locations (5)

Minnesota

  • Hennepin Healthcare Research Institute — Minneapolis
  • Regents of the University of Minnesota - Advanced Research & Diagnostic — Minneapolis

Georgia

  • Foundation for Atlanta Veterans Education and Research, Inc. — Decatur

North Carolina

  • Wake Forest University — Winston-Salem

Victoria

  • Monash University — Melbourne

Trial Details

FieldValue
Enrollment Target 13,435 participants
Start Date 2022-07-01
Est. Completion 2027-08

Sponsor

Anne Murray

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07224139

The ClinicalTrials.gov registry entry for NCT07224139 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 13,435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anne Murray, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07224139 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Minnesota, Georgia, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07224139 about?

NCT07224139 is a clinical study titled "Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias". Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for persona...

What is the current status of trial NCT07224139?

This trial is currently active not recruiting. The enrollment target is 13,435 participants. The study started on 2022-07-01. Estimated completion is 2027-08.

What conditions does trial NCT07224139 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Dysfunction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT07224139?

This trial is sponsored by Anne Murray, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07224139 being conducted?

This trial has 5 study locations across Georgia, Minnesota, North Carolina, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial